United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

2:18pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BLUE.OQ


bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and... (more)


Beta: 2.12
Market Cap(Mil.): $2,654.26
Shares Outstanding(Mil.): 40.59
Dividend: --
Yield (%): --


  BLUE.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -6.47 -- --
ROI: -26.10 -1.38 14.86
ROE: -30.24 -1.07 16.28

Medigene eyeing more immunotherapy deals after Bluebird pact

FRANKFURT German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.

Dec 19 2016

Wall Street little changed as bank rally pauses

U.S. stocks ended little changed on Friday after a payrolls report did little to recast expectations for an interest rate hike from the Federal Reserve this month and bank stocks cooled to round out their fourth straight week of gains. | Video

Dec 02 2016

Bluebird, Celgene myeloma treatment impresses in tiny study

Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.

Nov 30 2016

BRIEF-Bluebird Bio qtrly loss per share $2.07

* Says HGB-207 and all studies of lentiglobin to incorporate manufacturing process 2 going forward

Nov 02 2016

BRIEF-Bluebird Bio provides update on Lentiglobin programs

* Bluebird Bio provides update on Lentiglobin programs and research and development strategy at gene therapy day

Oct 13 2016

BRIEF-Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program

* LentiGlobin(TM) investigational gene therapy for transfusion-dependent beta-thalassemia accepted into European Medicines Agency's PRIME program Source text for Eikon: Further company coverage:

Sep 21 2016

BRIEF-Bluebird bio reports qtrly loss per share of $1.59

* Bluebird bio reports second quarter 2016 financial results and recent operational progress

Aug 03 2016

Earnings vs. Estimates